Treatment of lateral epicondylitis with botulinum toxin. A randomized, double-blind, placebo-controlled trial

被引:106
|
作者
Wong, SM [1 ]
Hui, ACF [1 ]
Tong, PY [1 ]
Poon, DWF [1 ]
Yu, E [1 ]
Wong, LKS [1 ]
机构
[1] Chinese Univ Hong Kong, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China
关键词
D O I
10.7326/0003-4819-143-11-200512060-00007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Lateral epicondylitis is a common condition for which botulinum toxin has been reported to have a therapeutic role in uncontrolled studies. Objective: To determine if an injection of botulinum toxin is more effective than placebo for reducing pain in adults with lateral epicondylitis. Design: Randomized, double-blind, placebo-controlled trial conducted from September 2002 to December 2004. Setting: Outpatient clinics at a university hospital and a district hospital in Hong Kong. Participants: 60 patients with lateral epicondylitis. Measurements: The primary outcome was change in subjective pain as measured by a 100-mm visual analogue scale (VAS) ranging from 0 (no pain) to 10 (worst pain ever) at 4 weeks and 12 weeks. All patients completed post-treatment follow-up. Interventions: A single injection of 60 units of botulinum toxin type A or normal saline placebo. Results: Mean VAS scores for the botulinum group at baseline and at 4 weeks were 65.5 mm and 25.3 mm, respectively; respective scores for the placebo group were 66.2 mm and 50.5 mm (between-group difference of changes, 24.4 mm [95% CI, 13.0 to 35.8 mm]; P < 0.001). At week 12, mean VAS scores were 23.5 mm for the botulinum group and 43.5 mm 1:or the placebo group (between-group difference of changes, 19.3 mm [CI, 5.6 to 32.9 mm]; P = 0.006). Grip strength was not statistically significantly different between groups at any time. Mild paresis of the fingers occurred in 4 patients in the botulinum group at 4 weeks. One patient's symptoms persisted until week 12, whereas none of the patients receiving placebo had the same complaint. At 4 weeks, 10 patients in the botulinum group and 6 patents in the placebo group experienced weak finger extension on the same side as the injection site. Limitations: The trial was small, and most participants were women. The blinding protocol may have been ineffective because the 4 participants who experienced paresis of the fingers could have correctly assumed that they received an active treatment. Conclusions: Botulinum toxin injection may improve pain over a 3-month period in some patients with lateral epicondylitis, but injections may be associated with digit paresis and weakness of finger extension.
引用
收藏
页码:793 / 797
页数:5
相关论文
共 50 条
  • [21] Double-blind, placebo-controlled, pilot trial of botulinum toxin a in restless legs syndrome
    Nahab, Fatta B.
    Peckham, Elizabeth L.
    Hallett, Mark
    NEUROLOGY, 2008, 71 (12) : 950 - 951
  • [22] EFFECTS OF BOTULINUM TOXIN A IN AMBULANT ADULTS WITH SPASTIC CEREBRAL PALSY: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL
    Maanum, Grethe
    Jahnsen, Reidun
    Stanghelle, Johan K.
    Sandvik, Leiv
    Keller, Anne
    JOURNAL OF REHABILITATION MEDICINE, 2011, 43 (04) : 338 - 347
  • [23] Treatment of Neuropsychiatric Symptoms in Parkinson's Disease With Botulinum Toxin A: A 12 week Randomized, Double-Blind, Placebo-Controlled Trial
    Zhu, Xiaofeng
    Wei, Ming
    Wang, Lijun
    Tong, Qiang
    Yang, Xiu
    Han, Qiu
    JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY, 2025, 38 (03) : 223 - 231
  • [24] Botulinum Toxin A in Postherpetic Neuralgia A Parallel, Randomized, Double-Blind, Single-Dose, Placebo-controlled Trial
    Apalla, Zoe
    Sotiriou, Elena
    Lallas, Aimilios
    Lazaridou, Elizabeth
    Ioannides, Demetrios
    CLINICAL JOURNAL OF PAIN, 2013, 29 (10): : 857 - 864
  • [25] Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial
    Maari, Catherine
    Marchessault, Philippe
    Bissonnette, Robert
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (06) : 1139 - 1141
  • [26] TREATMENT OF LATERAL EPICONDYLITIS WITH INJECTION OF PLATELET-RICH PLASMA OR CORTICOSTEROID VERSUS SALINE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    Krogh, T.
    Fredberg, U.
    Stengaard-Pedersen, K.
    Christensen, R.
    Ellingsen, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 620 - 620
  • [27] Treatment of Lateral Epicondylitis with Injection of Platelet-Rich Plasma or Corticosteroid Versus Saline: A Randomized, Double-Blind, Placebo-Controlled Trial
    Krogh, Thoger
    Fredberg, Ulrich
    Stengaard-Pedersen, Kristian
    Jensen, Pia
    Christensen, Robin
    Ellingsen, Torkell
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S415 - S416
  • [28] Botulinum toxin A in the prophylactic treatment of migraine - a randomised, double-blind, placebo-controlled study
    Schwaag, S
    Vollmer-Haase, J
    Rahmann, A
    Frese, A
    Husstedt, IW
    Evers, S
    CEPHALALGIA, 2003, 23 (07) : 702 - 702
  • [29] Randomized, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosis
    Jessica Mandrioli
    Roberto D’Amico
    Elisabetta Zucchi
    Sara De Biasi
    Federico Banchelli
    Ilaria Martinelli
    Cecilia Simonini
    Domenico Lo Tartaro
    Roberto Vicini
    Nicola Fini
    Giulia Gianferrari
    Marcello Pinti
    Christian Lunetta
    Francesca Gerardi
    Claudia Tarlarini
    Letizia Mazzini
    Fabiola De Marchi
    Ada Scognamiglio
    Gianni Sorarù
    Andrea Fortuna
    Giuseppe Lauria
    Eleonora Dalla Bella
    Claudia Caponnetto
    Giuseppe Meo
    Adriano Chio
    Andrea Calvo
    Andrea Cossarizza
    Nature Communications, 14 (1)
  • [30] Randomized, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosis
    Mandrioli, Jessica
    D'Amico, Roberto
    Zucchi, Elisabetta
    De Biasi, Sara
    Banchelli, Federico
    Martinelli, Ilaria
    Simonini, Cecilia
    Lo Tartaro, Domenico
    Vicini, Roberto
    Fini, Nicola
    Gianferrari, Giulia
    Pinti, Marcello
    Lunetta, Christian
    Gerardi, Francesca
    Tarlarini, Claudia
    Mazzini, Letizia
    De Marchi, Fabiola
    Scognamiglio, Ada
    Soraru, Gianni
    Fortuna, Andrea
    Lauria, Giuseppe
    Dalla Bella, Eleonora
    Caponnetto, Claudia
    Meo, Giuseppe
    Chio, Adriano
    Calvo, Andrea
    Cossarizza, Andrea
    NATURE COMMUNICATIONS, 2023, 14 (01)